中国合理用药探索2026，Vol.23Issue(7)：21-27,7.DOI:10.3969/j.issn.2096-3327.2026.07.004
依洛尤单抗联合瑞舒伐他汀对冠心病合并血脂异常患者脂质代谢指标及心功能的影响
Effects of Evolocumab Combined with Rosuvastatin on Lipid Metabolism Indices and Cardiac Function in Patients with Coronary Heart Disease and Hyperlipidemia
摘要
Abstract
Objective:To investigate the effects of evolocumab combined with rosuvastatin on lipid metabolism indices and cardiac function in patients with coronary heart disease(CHD)and hyperlipidemia.Methods:This prospective randomized controlled trial enrolled 124 patients with CHD and hyperlipidemia treated at a hospital from July 2022 to July 2024.Using a random number table method,the patients were assigned to a control group receiving rosuvastatin or an observation group receiving evolocumab plus rosuvastatin,with 62 cases in each group.Changes from before to after treatment in serum lipid parameters[low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),and total cholesterol(TC)],lipid metabolism indices[apolipoprotein(Apo)A1 and ApoB],and cardiac function parameters[left ventricular ejection fraction(LVEF)and left ventricular end-diastolic diameter(LVEDD)],as well as the incidences of major adverse cardiovascular event(MACE)and adverse reactions were compared between the groups.Results:After treatment,LDL-C,TC,ApoB,and LVEDD were decreased in both groups and were lower in the observation group than those in the control group(P<0.05).HDL-C,ApoA1,and LVEF were increased in both groups and were higher in the observation group compared with those in the control group(P<0.05).No statistical differences were exhibited in the overall incidence of MACE and overall incidence of adverse reactions between the two groups(P>0.05).Conclusion:Evolocumab combined with rosuvastatin effectively improves serum lipids and lipid metabolism indices and further improves cardiac function in patients with CHD and hyperlipidemia without increasing the risk of adverse drug reactions.关键词
冠心病/血脂异常/依洛尤单抗/瑞舒伐他汀/载脂蛋白/心功能Key words
coronary heart disease/hyperlipidemia/evolocumab/rosuvastatin/apolipoprotein/cardiac function分类
医药卫生引用本文复制引用
卢志强,孔深柯,王焕东,卫曼曼,赵强,李朋真..依洛尤单抗联合瑞舒伐他汀对冠心病合并血脂异常患者脂质代谢指标及心功能的影响[J].中国合理用药探索,2026,23(7):21-27,7.基金项目
河南省医学科技攻关计划项目(LHGJ20210229) （LHGJ20210229）
